logo UKRAIN®

can be reversed



Nowicky Pharma (FZE)

P.O. Box 48748,
Dubai Marina
United Arab Emirates

No: 01-01-02951

Inventor and patent owner
Dr. Wassil Nowicky
Margaretenstr. 7, A-1040 Vienna, Austria
Tel.: (+43 1) 586 12 23 Fax: (+43 1) 586 89 94



Study I

90 patients with histologically verified inoperable pancreatic cancer were treated in a controlled, randomized study at the University of Ulm (Germany). Patients in Group A received the chemotherapeutic drug Gemcitabine 1000 mg/m2, those in Group В received 20 mg UKRAIN, and those in Group C received 1000 mg/m2 Gemcitabine followed by 20 mg UKRAIN per week. Survival rates after 6 months were 26% in Group A, 65% in Group В and 74% in Group C. The results showed that in inoperable advanced pancreatic cancer, survival rates were doubled using UKRAIN in combination with Gemcitabine ( 183). Patients were further observed after the conclusion of the study and it was noted that UKRAIN was well tolerated and could be administered without problem to all patients. UKRAIN brought about a significant increase in survival time in comparison to therapy with Gemcitabine alone. Combination therapy with Gemcitabine and UKRAINE showed no advantage over monotherapy with UKRAIN. As a consequence of the results of this study the doctors from the University of Ulm recommend UKRAIN monotherapy in the palliative treatment of advanced pancreatic cancer ( 188).

Study II

42 patients with pathologically verified pancreatic cancer were treated in a randomised study carried out by Prof. Zemskov (National Medical University Kiev, Ukraine). One group received vitamin C plus UKRAIN, the remainder (the control group) vitamin C plus a normal saline solution. The UKRAIN therapy dose was 10 mg intravenously every second day, to a total of 100 mg per patient. The survival rate after one year was 76% in the group treated with UKRAIN as opposed to 9.5% in the control group. The survival rate after two years was 48% in the UKRAIN-treated group and 5% in the control group ( 186).



Prognosis of standard treatment

From Wikipedia, the free encyclopedia

Patients diagnosed with pancreatic cancer typically have a poor prognosis partly because the cancer usually causes no symptoms early on, leading to metastatic disease at time of diagnosis. Median survival from diagnosis is around 3 to 6 months; 5-year survival is much less than 5% [6]. With 32,180 new diagnoses in the United States every year, and 31,800 deaths, mortality approaches 99%, giving pancreatic cancer the #1 fatality rate of all cancers and the #4 cancer killer in the United States amongst both men and women. [7]

Pancreatic cancer occasionally may result in diabetes. Insulin production is hampered and it has been suggested that the cancer can also prompt the onset of diabetes and vice versa. [8]